08/10/2023

Immatics beginnt klinische Phase-1/2-Studie zur Untersuchung des bispezifischen TCR-Kandidaten IMA402 gegen die Zielstruktur PRAME bei Patienten mit fortgeschrittenen soliden Tumoren

Tübingen, Deutschland und Houston, Texas, 10. August 2023 – Immatics N.V. (NASDAQ: IMTX, „Immatics“), ein Unternehmen, das sich auf die Entwicklung und Herstellung von T-...
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required
0 / 2048
This field is required

You hereby consent to us (imprint) processing your data in accordance with the detailed explanation and information (see point 6. Registration for an event there). In particular, you consent to BioRegio STERN processing the personal data provided by you as part of the registration for an event. We use the data provided in the registration for your participation in the event, i.e. e.g. for keeping lists of participants (only used internally).
Giving consent is completely voluntary. You have the right to revoke your consent at any time. The revocation of consent does not affect the lawfulness of the processing carried out on the basis of the consent until the revocation. You can declare your revocation, for example, at our premises, by letter to BioRegio STERN Management GmbH, Friedrichstr. 10, 70174 Stuttgart, Germany, or by e-mail to info@bioregio-stern.de or fax to fax number 0711-870354-44.
You have the right to object to the processing of data that we process on the basis of a legitimate interest. *

* Without filling in or ticking the fields or boxes marked with an asterisk (" * "), your application is not complete and cannot be processed by us."

If you have any questions, please contact Dr. Margot Jehle: jehle@bioregio-stern.de, phone +49-711-870354-29.

An error occurred and processing did not complete.

Sorry, the english version of this page is currently not available.

This field is required
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required
0 / 2048
This field is required

You hereby consent to us (imprint) processing your data in accordance with the detailed explanation and information (see point 6. Registration for an event there). In particular, you consent to BioRegio STERN processing the personal data provided by you as part of the registration for an event. We use the data provided in the registration for your participation in the event, i.e. e.g. for keeping lists of participants (only used internally).
Giving consent is completely voluntary. You have the right to revoke your consent at any time. The revocation of consent does not affect the lawfulness of the processing carried out on the basis of the consent until the revocation. You can declare your revocation, for example, at our premises, by letter to BioRegio STERN Management GmbH, Friedrichstr. 10, 70174 Stuttgart, Germany, or by e-mail to info@bioregio-stern.de or fax to fax number 0711-870354-44.
You have the right to object to the processing of data that we process on the basis of a legitimate interest. *

* Without filling in or ticking the fields or boxes marked with an asterisk (" * "), your application is not complete and cannot be processed by us."

If you have any questions, please contact Dr. Margot Jehle: jehle@bioregio-stern.de, phone +49-711-870354-29.

An error occurred and processing did not complete.
07/20/2023

Anal Cancer Screening: New Microbiome-Associated Biomarkers Could Improve Prevention

A new study published in Nature Medicine, July 2023 has identified two novel markers for screening high-grade squamous intraepithelial lesions (HSIL), a precursor to anal...
07/20/2023

Mikrobiom-Forschung Neue Biomarker für das Analkrebs Screening entdeckt

Zwei neue Marker aus dem analen Mikrobiom von Menschen mit HIV (PWH) eröffnen neue Möglichkeiten für das Screening hochgradiger squamöser intraepithelialer Läsionen (HSIL...
08/01/2023

CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK

CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”...